02:27 PM EDT, 09/03/2025 (MT Newswires) -- Immunovant ( IMVT ) reported "encouraging" data from its study of batoclimab to treat uncontrolled Graves' disease, showing normal thyroid functioning in the majority of the patients during a six-month off-treatment follow-up period.

Twenty-five patients received the monoclonal antibody for six months, followed by a 24-week off-treatment observation, and 17 of the 21 patients who entered the follow-up period maintained normal thyroid function, the company said Wednesday in a statement.

Of the 17 patients, 50% achieved complete remission without anti-thyroid drugs six months after stopping treatment, the company said.

The data provide "evidence of potential disease modification," George Kahaly, lead principal investigator, said in the statement.

The safety and tolerability of the drug candidate were consistent with earlier studies, the company said. The full data will be presented at the annual meeting of the American Thyroid Association on Sept. 11.

Immunovant ( IMVT ) shares rose 10% in recent Wednesday trading. Roivant Sciences ( ROIV ) , the majority owner of Immunovant ( IMVT ), climbed 1.5%.

Price: 16.57, Change: +1.50, Percent Change: +9.95